Handbook

R

Retatrutide

Retatrutide is a triple agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) receptors

It is being studied for the treatment of obesity, type 2 diabetes (T2D), and metabolic dysfunction-associated steatotic liver disease (MASLD), with potential applications for other metabolic conditions like non-alcoholic fatty liver disease (NAFLD), obstructive sleep apnea, and knee osteoarthritis

Unlike dual agonists like tirzepatide or single agonists like semaglutide, Retatrutide’s triple-receptor action aims to enhance weight loss, glycemic control, and metabolic health by synergistically regulating appetite, insulin secretion, glucose metabolism, and energy expenditure

One major benefit of Retatrutide is MUSCLE PRESERVATION. Unlike some weight loss drugs, Retatrutide may preserve lean muscle mass, reducing frailty risk

Mechanism of Action

GLP-1 Receptor Agonism: Stimulates insulin secretion (glucose-dependent), slows gastric emptying, suppresses appetite, and enhances satiety

GIP Receptor Agonism: Enhances insulin release post-meal, improves insulin sensitivity, and may contribute to weight loss

Glucagon Receptor Agonism: Increases energy expenditure, promotes fat mobilization, and reduces liver fat, while GLP-1/GIP activity prevents hyperglycemia

Research application

Copied from the handbook as research notes. and not instructions.

10mg vial

  • 2mL of BAC water
  • 2mg = 40 units
  • 4mg = 80 units
  • 6mg = 120 units

30mg vial

  • 3mL BAC water
  • 1mg = 10 units
  • 2mg = 20 units
  • 3mg = 30 units

Etc

50mg vial

  • 3mL BAC wafer
  • 1mg = 6 units
  • 2mg = 12 units
  • 3mg = 18 units

Etc

60mg vial

  • 3mL BAC water
  • 1mg = 5 units
  • 2mg = 10 units
  • 3mg = 15 units

Etc

  • Weeks 1-4: 1mg once weekly. Starting dose to asses tolerance
  • Weeks 5-8: 2mg once weekly. Gradually increase if tolerated
  • Weeks 9-12: 4mg once weekly. Midrange dose
  • Weeks 13+: 8mg or 12mg once weekly

Phase 3 trails of Retatrutide have reported participant use as long as 68 to 80 weeks

Unless other wise noted intermuscular (IM) peptides are commonly administered via subcutaneous (SQ) injection with 30-31 gauge syringes

From @BowTiedYukon

Read this first

The information provided is for educational and informational purposes only and is not medical advice. Always consult with your physician or a qualified healthcare provider before starting any health protocol or using any peptides

YOU assume full responsibility for YOUR actions and decisions. Do YOUR own research and make informed choices in consultation with a licensed medical professional

This guide is an independent work created by the author. It is not affiliated with, endorsed by, or associated with any company or organization

All peptides discussed are intended for research use only. They are not intended for human or animal consumption or for use in any diagnostic or therapeutic purposes

Unless other wise noted intermuscular (IM) peptides are commonly administered via subcutaneous (SQ) injection with 30-31 gauge syringes

This app is an alphabetical reader for BowTiedYukon’s free Peptide Handbook. It is not affiliated with Elite Research USA. His profile lists the code YUKON10.

@BowTiedYukon